We are live on ! Find out more
BRTX icon

BioRestorative Therapies
BRTX

14 hedge funds and large institutions have $966K invested in BioRestorative Therapies in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more capital invested

Capital invested by funds: $849K → $966K (+$117K)

0.9% less ownership

Funds ownership: 8.43% → 7.53% (-0.9%)

7% less funds holding

Funds holding: 15 → 14 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
14
Holders Change
-1
Holders Change %
-6.67%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
+$89.3K
2
State Street
State Street
Massachusetts
+$62.8K
3
Two Sigma Investments
Two Sigma Investments
New York
+$52.2K
4
UBS Group
UBS Group
Switzerland
+$4.89K

Top Sellers

Rank Fund Capital Flow
1
AC
Ayrton Capital
Connecticut
-$114K
2
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$77K
3
BFM
Boothbay Fund Management
New York
-$33.8K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$27.9K
5
TRCT
Tower Research Capital (TRC)
New York
-$9.11K

BRTX Hedge Fund Activity: Q1 2023 in Review

14 of the 6,279 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q1 2023, worth a combined $966K — up 14% from $849K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BRTX and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $89.3K. The largest seller was Ayrton Capital, exiting entirely with an estimated $114K sold.

  • 14 institutional investors held BioRestorative Therapies (BRTX) as of Q1 2023, down from 15 in Q4 2022.
  • Funds reported $966K of BioRestorative Therapies stock for Q1 2023, up 14% quarter-over-quarter.
  • 3 funds opened new BioRestorative Therapies positions in Q1 2023 and 4 closed out, a net change of -1 holder.
  • The largest BioRestorative Therapies buyer in Q1 2023 was Two Sigma Advisers, an estimated $89.3K added.
  • The largest BioRestorative Therapies seller in Q1 2023 was Ayrton Capital, an estimated $114K sold.

Based on aggregated 13F filings for Q1 2023.